<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!-- saved from url=(0581)http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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 -->
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Ovid: Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells.</title>
<link rel="stylesheet" type="text/css" href="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovid.csspack.css">
<!--[if lt IE 10]>
<link rel="stylesheet" type="text/css" href="./styles/ie-fixup-9.css">
<![endif]-->
<!--[if lt IE 9]>
<link rel="stylesheet" type="text/css" href="./styles/unicode-ie.css">
<![endif]-->
<!--[if lt IE 9]>
<link rel="stylesheet" type="text/css" href="./styles/ie-fixup-8.css">
<![endif]-->
<!--[if lt IE 8]>
<link rel="stylesheet" type="text/css" href="./styles/ie-fixup-7.css">
<![endif]-->
<!--[if lt IE 7]>
<link rel="stylesheet" type="text/css" href="./styles/ie-fixup-6.css">
<![endif]-->
<!--[if lte IE 7]>
<link rel="stylesheet" href="./styles/jquery.tabs-ie.css" type="text/css" media="projection, screen">
<![endif]-->
<script src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/AppMeasurement.js"></script><script src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/OmnitureTracker.js"></script><script src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/BrightcoveExperiences.js"></script><script type="text/javascript" src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovid.jspack.min.js"></script>
<script type="text/javascript">$().ready( function() { general_ready() } );</script>

<meta name="ROBOTS" content="NOFOLLOW,NOARCHIVE">
<meta name="OvidPageId" content="ArticleFulltext">
<meta name="Ovid_BRANCHID" content="OvidSP_UI03.25.00">
<meta name="Ovid_BUILDID" content="OvidSP_UI03.25.00.058">
<meta name="Ovid_SOURCE_BRANCH" content="branches/OvidSP_UI-Janus">
<meta name="Ovid_SOURCE_DATEGMT" content="2017-04-07@08:02:57">
<meta name="Ovid_SOURCE_ID" content="108203">
<meta name="Ovid_SessionInterface" content="OvidSP">
<link id="ovidwsurl" rel="service" class="preferred" type="application/x-ovid-ovidws" href="https://ovidsp.tx.ovid.com/ovidws">
<meta name="OvidWS_Session_Cookie" content="LKEAFPCDGPDDLONENCGKKBGCDDMIAA00">
<meta name="MyProjectsEnabled" content="YES">
<meta name="MyProjectsActive" content="NO">
<meta name="MyProjectsAllowUploads" content="NO">
<meta name="MyProjectsForbiddenTypes" content=".dll,.exe,.zip">
<link id="base_ui_callback_url" rel="baseurl" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00">
<meta name="heartbeat-interval" content="450000">
<meta name="check-ajax">
<meta name="OvidPageId" content="JnlFullText"></head>
<body>
<a id="skipto" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#below-banner">Skip to Content</a> <input type="hidden" id="Ovid_PageId" value="ArticleFulltext">
<input type="hidden" id="pageName" value="search full text">
<input type="hidden" id="userName" value="">
<input type="hidden" id="userId" value="">
<input type="hidden" id="groupName" value="cne999">
<input type="hidden" id="groupId" value="4296800">
<input type="hidden" id="AuthenticationType" value="IP">
<input type="hidden" id="omniture_site_id" value="wkmedovidsp,wkmedmrglobal">
<input type="hidden" id="omniture_site" value="OvidSP">
<input type="hidden" id="omniture_division" value="MR">
<script type="text/javascript">
    function set_JnlFullText() {
        metaTag = document.createElement('meta');
        metaTag.setAttribute('name','OvidPageId');
        metaTag.setAttribute('content','JnlFullText');
        head = document.getElementsByTagName('head')[0];
        head.appendChild(metaTag);
        return;
    }
    if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+)
        // Firefox throws an uncaught exception error executing this
        // code, even though it seems to work. Adding a  do nothing
        // try/catch clause around it for now, since  the exection itself
        // appears to be innocuous
        try {
            window.addEventListener("onload",set_JnlFullText(),false);
        } catch(e) {}
    } else if (window.attachEvent) { // IE 5+ Event Model
         window.attachEvent("onload",set_JnlFullText);
    } // For anything else, just don't add the event
</script>
    <div id="header">
    <table border="0" cellpadding="0" cellspacing="0">
        <tbody><tr id="header-block">
            <td id="header-new-logo">
                <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/wkh_ovidsp_new_logo.png" alt="OVID SP">
            </td>
            <td id="header-nav">
            <table border="0" cellpadding="0" cellspacing="0">
            <tbody><tr id="header-nav-whk-logo">
                <td id="header-whk-logo">
                    <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/wkh_logo.png" alt="Wolters Kluwer">
                </td>
            </tr>
            <tr id="header-nav-content">
                <td id="header-buttons-upper"><a class="tlink" target="_parent" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Access+Personal+Account=1" name="Access Personal Account">My Account</a><a class="tlink" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;PayPerView+Account=1" name="PayPerView Account">My PayPerView</a><a class="tlink" href="http://www.ovid.com/site/resources/index_support.jsp" target="knowledgebase"> Support &amp; Training</a><a class="help-link tlink" target="_blank" help="fulltext" href="http://site.ovid.com/site/help/documentation/osp/en/index.htm#CSHID=fulltext.htm|StartTopic=Content/fulltext.htm|SkinName=OvidSP_WebHelp_Skin">Help</a><a class="logofflast" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Logoff=1&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00">Logoff</a></td>
            </tr>
            </tbody></table>
        </td></tr>
    </tbody></table>
</div>
<div id="header-tabs-container" class="clearfix"><div id="top-tab">
<ul class="top">
<li><a href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;C=_main&amp;tab=search&amp;Main+Search+Page=1" class="tlink">Search</a></li>
<li><a href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;tab=journals&amp;C=yrovft&amp;Jump+to+Browse=yrovft&amp;New+Database=S.dbListAll%7cSingle%7c13" class="tlink">Journals</a></li>
<li><a href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;tab=multimedia&amp;C=mmdb&amp;Jump+to+Browse=mmdb&amp;New+Database=S.dbListAll%7cSingle%7c3" class="tlink">Multimedia</a></li>
<li><a href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;C=_main&amp;tab=workspace.projects&amp;Projects+Main+Page=1" class="tlink">My Workspace</a></li>
<li><a href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;C=_main&amp;tab=mobile&amp;Ovid+Today+Page=1" class="tlink">Mobile</a></li></ul></div>
</div>
<div id="below-banner"><div id="main-content"><div id="overlay-container" class="hide"></div><div id="mm-overlay-container" class="hide"></div><form id="main-form" method="post" enctype="application/x-www-form-urlencoded" accept-charset="UTF-8" action="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi">
<input type="hidden" id="S" name="S" value="LKEAFPCDGPDDLONENCGKKBGCDDMIAA00">
<input type="hidden" id="WebLinkReturn" name="WebLinkReturn" value="Full Text=L|S.sh.22.23|0|00005344-199910000-00004">
<input type="hidden" id="ftdoc" name="ftdoc" value="L|S.sh.22.23|0|00005344-199910000-00004">
<input type="hidden" id="an" name="an" value="00005344-199910000-00004">
<input type="hidden" id="resultset" name="resultset" value="S.sh.22|1">
<a name="toc"></a>


<div class="fulltext-searchresult-holder">



     
         <div class="fulltext-breadcrumb-left">
           <a target="_top" class="tlink fulltext-breadcrumb-searchlink fulltext-breadcrumb-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Current+Search+Results=1" title="">&lt; Back to Search Results</a>
         </div>
     
     
       
         
       
    



</div>


<table id="fulltext-container-main">

 <tbody><tr>

  <td id="fulltext-main">

<div id="fulltext-headers">

<div id="fulltext-sourceinfo">
    <div id="fulltext-source-info">
      <div id="fulltext-source-right-top">
<a name="0"></a>

<div class="fulltext-SOURCEFULL">
<h1>  Journal of Cardiovascular Pharmacology  
</h1>
</div>

      <div>Issue: Volume 34(4),&nbsp;October 1999,&nbsp;pp 497-504</div>
      <div>Copyright: © 1999 Lippincott Williams &amp; Wilkins, Inc.</div>
      <div>Publication Type: [Articles]</div>
      <div>ISSN: 0160-2446</div>
      <div>Accession: 00005344-199910000-00004</div>
      <div>Keywords: Cilostazol, Milrinone, OPC-13015, Phosphodiesterase, Platelet, Heart, Ventricular myocytes</div>       </div>
    </div><!-- "fulltext-source-info" -->
    <div id="fulltext-source-info-bottom">
    </div><!-- "fulltext-source-info-bottom" -->
</div> <!-- "fulltext-sourceinfo" -->

<div class="fulltext-navbar">

 <span class="fulltext-navbar-doctype">[Articles]</span>



<span class="fulltext-navbar-toclinks">


    <a class="tlink fulltext-navbar-links-prev" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Full+Text+Link=S.sh.22.24%7c3%7csl_10%7c80%7c2" title="Direct Block of Ca2+ Channels by Calmidazolium in Cultured Vascular Smooth Muscle Cells.">
       &lt; Previous Article
    </a>



    <a class="tlink fulltext-navbar-links-toc" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;TOC=S.sh.22.24%7c4%7c60">Table of Contents</a>



    <a class="tlink fulltext-navbar-links-next" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Full+Text+Link=S.sh.22.24%7c5%7csl_10%7c80%7c2" title="Modulation of Adrenergic Receptors During Left Ventricular Hypertrophy Development and After Regression by Captopril.">Next Article &gt;</a>


</span>




</div>


</div> <!-- "fulltext-headers" -->


  
    
        
<a name="5"></a>

<div class="fulltext-TITLE">
<h2>  Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells  
</h2>
</div>

    
  

  
    
        
<a name="7"></a>

<div class="fulltext-AUTHOR">
<h3>  Cone, James; Wang, Sheng; Tandon, Narendra; Fong, Miranda; Sun, Bing; Sakurai, Kazushi; Yoshitake, Masuhiro; Kambayashi, Jun-ichi; Liu, Yongge  
</h3>
</div>

    
  



  
    <div class="fulltext-INSTITUTION-header widget-ctl fulltext-widget-open">Author Information </div>
    <div class="fulltext-INSTITUTION-contentbody">
    
        
<a name="8"></a>

<div class="fulltext-INSTITUTION fulltext-INDENT">  Maryland Research Laboratories, Otsuka America Pharmaceutical Inc., Rockville, Maryland, U.S.A.  
</div>

    
        
<a name="9"></a>

<div class="fulltext-INSTITUTION fulltext-INDENT">  Received March 3, 1999; revision accepted May 24, 1999.  
</div>

    
        
<a name="10"></a>

<div class="fulltext-INSTITUTION fulltext-INDENT">  Address correspondences and reprint requests to Dr. Y. Liu at Maryland Research Laboratories, Otsuka America Pharmaceutical, Inc., 9900 Medical Center Drive, Rockville, MD 20850, U.S.A. E-mail: yonggel@mrl.oapi.com  
</div>

    
    </div>
  

  

<!-- body.tt2 begin -->
<div id="fulltext-body">
                <div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="11"></a>

<div class="fulltext-LEVEL1 widget-ctl fulltext-widget-open">
<h4>Summary:
</h4>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="12"></a>

<p class="fulltext-ABSTRACT fulltext-INDENT">Cilostazol is a potent cyclic nucleotide phosphodiesterase (PDE) type 3 (PDE3) inhibitor that was recently approved by the Food and Drug Administration (FDA) for the treatment of intermittent claudication. Its efficacy is presumed to be due to its vasodilatory and platelet activation inhibitory activities. Compared with those treated with placebo, patients treated with cilostazol showed a minimal increase in cardiac adverse events. Because of its PDE3 inhibitory activity, however, the possibility that cilostazol exerts positive cardiac inotropic effects is a safety concern. Therefore we compared the effects of cilostazol with those of milrinone, a selective PDE3 inhibitor, on intracellular cyclic adenosine monophosphate (cAMP) levels in platelets, cardiac ventricular myocytes, and coronary smooth muscle cells. We also compared the corresponding functional changes in these cells. Cilostazol and milrinone both caused a concentration-dependent increase in the cAMP level in rabbit and human platelets with similar potency. Furthermore, cilostazol and milrinone were equally effective in inhibiting human platelet aggregation with a median inhibitory concentration (IC<sub class="fulltext-SB">50</sub>) of 0.9 and 2 µ<span class="fulltext-IT">M,</span> respectively. In rabbit ventricular myocytes, however, cilostazol elevated cAMP levels to a significantly lesser extent (p &lt; 0.05 vs. milrinone). By using isolated rabbit hearts with a Langendorff preparation, we showed that milrinone is a very potent cardiotonic agent; it concentration-dependently increased left ventricular developed pressure (LVDP) and contractility. Cilostazol was less effective in increasing LVDP and contractility (p &lt; 0.05 vs. milrinone), which is consistent with the cardiac cAMP levels. The cardiac effect of OPC-13015, a metabolite of cilostazol with about sevenfold higher PDE3 inhibition, was similar to cilostazol. Whereas milrinone concentration-dependently increased cAMP in rabbit coronary smooth muscle cells, cilostazol did not have such an effect. However, both compounds increased coronary flow equally in rabbit hearts. Our results show that although cilostazol and milrinone both inhibit PDE3, cilostazol preferentially acts on vascular elements (platelets and flow). This unique profile of cilostazol is consistent with its beneficial and safe clinical outcomes in patients with intermittent claudication.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="13"></a>

<hr class="fulltext-LINESOLID"><br>
            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="14"></a>

<p class="fulltext-TEXT fulltext-INDENT">Cilostazol (OPC-13013, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril) has been used in Japan and other Asian countries for the treatment of lower-extremity peripheral arterial occlusive disease (PAOD) <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#57">(1-3)</a>. Intermittent claudication is the most common debilitating symptom of PAOD <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#60">(4)</a>. Patients with intermittent claudication are severely impaired in their ability to walk and perform daily activities <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#61">(5)</a>. Recent clinical trials have shown that cilostazol significantly improves exercise performance in intermittent claudication patients <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#62">(6-8)</a>, and it recently was approved by the Food and Drug Administration (FDA) for this indication <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#65">(9)</a>. Although the mechanism of action by which cilostazol exerts its beneficial effects is not fully understood, it is generally believed that it involves the inhibition of cyclic nucleotide phosphodiesterase (PDE) type 3 (PDE3) and a corresponding increase in intracellular cyclic adenosine monophosphate (cAMP) levels in platelets <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#63">(7,10,11)</a>. Elevation of intracellular cAMP in platelets inhibits platelet aggregation <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#68">(12)</a>. PDE3 also is a major PDE isoform in cardiac ventricular myocytes <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#69">(13-15)</a>. Elevation of intracellular cAMP in these cells increases contractility. Milrinone, as well as other PDE3 inhibitors, has been used as cardiotonic agents for heart failure patients <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#72">(16,17)</a>. These inhibitors have shown beneficial effects on relieving the symptoms, but long-term use in severe congestive heart failure patients is associated with proarrhythmic activities (possibly caused by excessive increase of intracellular cAMP in the heart) <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#74">(18)</a> and increased mortality <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#75">(19-21)</a>. Based on previous data of PDE3 inhibitors in heart failure patients, the FDA thus warned against the use of cilostazol by patients with heart failure. Although it is not known whether inhibition of PDE3 also would increase mortality in patients without severe congestive heart failure, the cardiac effects of cilostazol are still a concern, especially as the population of intermittent claudication patients may overlap with cardiac ischemic disease patients <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#78">(22,23)</a>.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="15"></a>

<p class="fulltext-TEXT fulltext-INDENT">In eight placebo-controlled clinical trials involving 2,702 patients (patients with heart failure were excluded), cilostazol showed an excellent safety profile with a minimal increase in cardiac adverse events (e.g., palpitation, tachycardia) and no increase in mortality <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#80">(24)</a>. Judging by the clinical experience, it may be possible that cilostazol is different from conventional PDE3 inhibitors, such as milrinone. To explore this possibility, we compared the ability of cilostazol and milrinone to increase intracellular cAMP in rabbit and human platelets, isolated rabbit ventricular myocytes, and rabbit coronary smooth muscle cells. We also studied the effects of these two agents on platelet aggregation and cardiac function in an isolated rabbit-heart model. Cilostazol has several metabolites, including OPC-13015, whose PDE3 inhibitory activity is sevenfold more potent than cilostazol with relatively high concentrations in plasma in vivo <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#80">(24)</a>. Thus the cardiac effects of OPC-13015 also were studied. Our results indicate that cilostazol preferentially affects vascular circulation with minimal effects on cardiac ventricular function. This is consistent with its beneficial and safe effects on patients with PAOD.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="16"></a>

<div class="fulltext-LEVEL1">
<h4>METHODS AND MATERIALS
</h4>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="17"></a>

<p class="fulltext-TEXT fulltext-INDENT">This study was conducted in accordance with the "Guide for the Care and Use of Laboratory Animals," published by the National Research Council, 1996, Washington DC, and approved by the Institutional Animal Care and Use Committee. For human blood donors, they signed consent forms in conformity with the Declaration of Helsinki.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="18"></a>

<div class="fulltext-LEVEL2">
<h5>Chemicals
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="19"></a>

<p class="fulltext-TEXT fulltext-INDENT">Cilostazol (lot 4576M) and OPC-13015 (lot 4F83M) were provided by Otsuka Pharmaceutical Co., Ltd., Tokushima, Japan. Collagenase (type II) was obtained from Worthington (Freehold, NJ, U.S.A.). Milrinone (lot 46H4097), ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), and all the other agents were purchased from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Cilostazol, OPC-13015, milrinone, and ODQ were dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 100 m<span class="fulltext-IT">M</span> (10 m<span class="fulltext-IT">M</span> for ODQ) and were diluted into buffer to achieve the final desired concentrations.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="20"></a>

<div class="fulltext-LEVEL2">
<h5>Cell preparation
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="21"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Platelets.</span> Peripheral blood samples were collected from six healthy volunteers (medication free) by a two-syringe technique, or five anesthetized rabbits (2-2.5 kg, New Zealand White) by using a 19G butterfly needle. Nine volumes of blood were drawn directly into a syringe containing one volume of 3.8% sodium citrate. Platelet-rich plasma (PRP) was obtained by centrifuging the whole blood at 150 <span class="fulltext-IT">g</span> (800 rev/min in a benchtop centrifuge, model TJ-6, Beckman Instruments, Inc., Fullerton, CA, U.S.A.) for 20 min at room temperature. PRP was recovered without disturbing the buffy coat and packed red blood cells, and EDTA and EGTA were added (final concentration of 1 m<span class="fulltext-IT">M</span>). The pH of the resultant PRP was reduced to 6.5 with citric acid (4 µl/ml of 1 <span class="fulltext-IT">M</span> stock) before the sedimentation of platelets at 1,000 <span class="fulltext-IT">g</span> (2,200 rpm) for 15 min. The platelet pellet was resuspended in 1/5 volumes of platelet-washing buffer (PWB, containing 128 m<span class="fulltext-IT">M</span> NaCl, 5.5 m<span class="fulltext-IT">M</span> dextrose, 4.26 m<span class="fulltext-IT">M</span> NaH<sub class="fulltext-SB">2</sub>PO<sub class="fulltext-SB">4</sub>, 7.46 m<span class="fulltext-IT">M</span> Na<sub class="fulltext-SB">2</sub>HPO<sub class="fulltext-SB">4</sub>, 4.77 m<span class="fulltext-IT">M</span> trisodium citrate, and 2.35 m<span class="fulltext-IT">M</span> citric acid, pH 6.5, containing 1 m<span class="fulltext-IT">M</span> EDTA, 1 m<span class="fulltext-IT">M</span> EGTA, and 0.5% BSA). The platelets were recovered by centrifugation at 800 <span class="fulltext-IT">g</span> in a fixed-speed centrifuge (Clay Adams Sero-Fuge II, Becton Dickinson and Company, Sparks, MD, U.S.A.) for 3.5 min. The supernatant was discarded, and the platelets were washed once with PWB. Finally the platelets were resuspended in Tyrode's HEPES buffer (136.7 m<span class="fulltext-IT">M</span> NaCl, 5.5 m<span class="fulltext-IT">M</span> dextrose, 2.6 m<span class="fulltext-IT">M</span> KCl, 13.8 m<span class="fulltext-IT">M</span> NaHCO<sub class="fulltext-SB">3</sub>, 1 m<span class="fulltext-IT">M</span> MgCl<sub class="fulltext-SB">2</sub>, 0.36 m<span class="fulltext-IT">M</span> NaH<sub class="fulltext-SB">2</sub>PO<sub class="fulltext-SB">4</sub>, and 10 m<span class="fulltext-IT">M</span> HEPES, pH 7.4), counted by using a Coulter ZM cell counter (Coulter Corporation, Hialeah, FL, U.S.A.), and platelet count was adjusted to 4 × 10<sup class="fulltext-SP">8</sup> platelets/ml.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="22"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Rabbit ventricular myocytes.</span> Isolated ventricular myocytes were obtained from rabbit hearts by conventional enzymatic dissociation methods <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#81">(25)</a>. In brief, hearts were quickly excised from anesthetized (30 mg/kg, i.v., pentobarbital) rabbits (New Zealand White) weighing 2-3 kg, and the aortas were cannulated for coronary perfusion on a Langendorff apparatus (Radnoti Glass Inc., Monrovia, CA, U.S.A.). The heart was perfused at 75 mm Hg of pressure with modified Krebs-Henseleitbicarbonate buffer solution composed of 118 m<span class="fulltext-IT">M</span> NaCl, 25 m<span class="fulltext-IT">M</span> NaHCO<sub class="fulltext-SB">3</sub>, 1.2 m<span class="fulltext-IT">M</span> KH<sub class="fulltext-SB">2</sub>PO<sub class="fulltext-SB">4</sub>, 4.75 m<span class="fulltext-IT">M</span> KCl, 1.2 m<span class="fulltext-IT">M</span> MgSO<sub class="fulltext-SB">4</sub>, 2 m<span class="fulltext-IT">M</span> CaCl<sub class="fulltext-SB">2</sub>, and 10 m<span class="fulltext-IT">M</span> dextrose. The perfusate was bubbled with 95% O<sub class="fulltext-SB">2</sub> and 5% CO<sub class="fulltext-SB">2</sub> and maintained at 37°C. After 5-min perfusion, the heart was perfused without Ca<sup class="fulltext-SP">2+</sup> for another 5 min, after which the perfusion solution was switched to one containing collagenase (0.8 mg/ml) for 20-30 min. The heart was then removed from the Langendorff apparatus, and the atria were trimmed away. The ventricles were minced into small pieces, and the suspension was incubated in a shaking bath at 37°C for another 10 min in collagenase-containing solution. Cells were filtered through a polyethylene mesh filter with a pore size of 200 µm. After washing with Ca<sup class="fulltext-SP">2+</sup>-free Krebs, Ca<sup class="fulltext-SP">2+</sup> was added back stepwise (0.25 m<span class="fulltext-IT">M</span> every 5 min) to a final concentration of 1 m<span class="fulltext-IT">M.</span> Cell viability (rod-shaped cells) was examined microscopically. Preparations with &gt;60% viability were used for subsequent experiments.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="23"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Rabbit coronary smooth muscle cells.</span> Cells were grown from explants of rabbit coronary arteries in Dulbecco's modified Eagle's medium (DMEM) with 10% bovine fetal serum <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#82">(26)</a>. Smooth muscle cells were confirmed by "hill-and-valley" growth pattern and an anti-[alpha]-actin antibody (Sigma A-2547). Passages four and five of cells were plated in six-well Falcon plates and grown to confluence.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="24"></a>

<div class="fulltext-LEVEL2">
<h5>Intracellular cAMP measurement
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="25"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Platelets.</span> First, 1 µl of one of the test agents (cilostazol or milrinone at 0.2, 0.6, 2, 6, and 20 m<span class="fulltext-IT">M</span> in DMSO) was aliquoted into separate polypropylene test tubes to final concentrations of 1, 3, 10, 30, and 100 µ<span class="fulltext-IT">M.</span> Tyrode's HEPES buffer and DMSO were used as controls. Each concentration point was assayed in duplicate. After prewarming at 37°C, 0.2 ml of platelet suspension was added to the tubes and mixed with a test agent by quickly vortexing. The tube was then incubated at 37°C for 3 min. The reaction was terminated by the rapid addition of 50 µl ice-cold 1.25N perchloric acid (PCA). After freeze-thawing once, the reaction mixtures were neutralized by mixing well with 50 µl of 1.25 <span class="fulltext-IT">M</span> KHCO<sub class="fulltext-SB">3</sub> and then centrifuged at 3,500 rev/min (2000 <span class="fulltext-IT">g</span>) for 15 min at 4°C. The resulting supernatants were collected and used for intracellular cAMP measurement. The cAMP concentration of the samples was measured by using a commercially available cAMP radioimmunoassay kit (NEK-033, DuPont NEN, Boston, MA, U.S.A.), according to the acetylated procedure described in the instructions from the manufacturer. Experiments were performed in duplicate.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="26"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Myocytes.</span> Myocytes were rinsed twice with HEPES-buffered Tyrode's solution (140 m<span class="fulltext-IT">M</span> NaCl, 5 m<span class="fulltext-IT">M</span> KCl, 1 m<span class="fulltext-IT">M</span> MgCl<sub class="fulltext-SB">2</sub>, 2 m<span class="fulltext-IT">M</span> CaCl<sub class="fulltext-SB">2</sub>, 10 m<span class="fulltext-IT">M</span> dextrose, and 10 m<span class="fulltext-IT">M</span> HEPES, pH 7.4) and resuspended in the same buffer at a density of 2 × 10<sup class="fulltext-SP">5</sup> cells/ml. Two microliters of one of the test agents (cilostazol and milrinone at 0.125, 0.375, 1.25, 3.75, and 12.5 m<span class="fulltext-IT">M</span> in 12.5% DMSO, except 12.5 m<span class="fulltext-IT">M</span> cilostazol in 62.5% DMSO for solubility reasons) were aliquoted separately into polypropylene test tubes to give a final concentration of 1, 3, 10, 30, and 100 µ<span class="fulltext-IT">M.</span> The corresponding concentrations of DMSO were used as controls. After prewarming at 37°C, 0.25 ml of the rabbit myocyte suspension was added to the tubes and mixed with the test agents by gentle vortexing. The tube was then incubated at 37°C for 10 min. The reaction was terminated by adding 50 µl of ice-cold 1.5N PCA. After freeze-thawing once, the reaction mixtures were neutralized by mixing well with 50 µl of 1.5 <span class="fulltext-IT">M</span> KHCO<sub class="fulltext-SB">3</sub> and then centrifuged at 3,500 rev/min (2000 <span class="fulltext-IT">g</span>) for 15 min at 4°C. The resulting supernatants were collected, and cAMP was measured by using the same method as mentioned for platelets. The myocytes from each rabbit were tested in duplicate.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="27"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Smooth muscle cells.</span> Cells were washed once with warm assay buffer (D-PBS with Ca<sup class="fulltext-SP">2+</sup>, Mg<sup class="fulltext-SP">2+</sup>, and glucose; Gibco, Gaithersburgh, MD, U.S.A.). Cells were then treated with cilostazol, milrinone, or vehicle (DMSO) for 10 min at 37°C. The medium was then aspirated, and 1 ml of ice-cold 0.1N HCl was added. The plates were placed on a shaker for 1 h at 4°C to extract intracellular cAMP. To minimize any PDE activity during the extraction, 1 m<span class="fulltext-IT">M</span> 3-isobutyl-1-methylxanthine (IBMX), a nonselective PDE inhibitor, was added into each well. The supernatants were obtained by centrifugation and used for cAMP measurement as mentioned for platelets. Experiments were performed in duplicate.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="28"></a>

<div class="fulltext-LEVEL2">
<h5>Platelet aggregation
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="29"></a>

<p class="fulltext-TEXT fulltext-INDENT">Washed platelet suspensions in Tyrode's HEPES buffer (3-4 × 10<sup class="fulltext-SP">8</sup> platelets/ml) were maintained at room temperature until use. All experiments were performed within 3-4 h after blood collection. The platelet suspension (300 µl) was transferred to the aggregation cuvettes and warmed at 37°C for 1 min before transferring the cuvette into the aggregation module of a four-channel aggregometer (AG10, Kowa Co., Nagoya, Japan) capable of measuring the kinetics of particle formation by laser scattering and aggregation by light transmission. Drug or vehicle was added to the sample such that the concentration of DMSO did not exceed 0.2%, and the sample was stirred with the drug for 1 min at 37°C before addition of the agonist. Aggregation was monitored for 6 min after the addition of 1 µg/ml collagen. Maximal light transmission at the end of 6 min was taken as a measure of aggregation. Aggregation values are presented as the percentage of control (vehicle) aggregation.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="30"></a>

<div class="fulltext-LEVEL2">
<h5>Isolated heart studies
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="31"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Langendorff preparation.</span> Male New Zealand White rabbits, weighing 1.4-2 kg, were used in this study. Rabbits were anesthetized with sodium pentobarbital (30 mg/kg) through a marginal ear vein, and the animals were then mechanically ventilated with a tracheal cannula. Hearts were exposed through a midline incision of the chest, quickly excised by an incision at the base of the heart, and put into ice-cold Krebs-Henseleit bicarbonate buffer. The heart was then attached to a Langendorff apparatus by the aortic root and perfused with nonrecirculating Krebs-Henseleit buffer at a constant pressure of 75 mm Hg. The perfusate was bubbled with 95% O<sub class="fulltext-SB">2</sub> and 5% CO<sub class="fulltext-SB">2</sub> gas mixture, and the bubbling rate was adjusted to maintain physiologic pH (7.35-7.45). Perfusate temperature was maintained at 38°C by a circulating water jacket surrounding the buffer reservoirs. The heart also was maintained at 38°C by a water-jacketed housing in which it was suspended. The open top of the jacket was covered with a piece of parafilm to maintain the humidity and temperature. The pulmonary artery was cannulated for coronary flow rate measurement. A saline-filled latex balloon, connected via a catheter to a pressure transducer, was inserted into the left ventricle and inflated to yield an end-diastolic pressure of 0-5 mm Hg. The pressure transducer was connected to a chart recorder (Model 7 polygraph, Grass Instrument Co., Quincy, MA, U.S.A.) to record left ventricular pressure and its first derivative (dp/dt) and heart rate. Coronary flow was measured by a timed collection of the effluent in a graduated cylinder. Hearts with left ventricular developed pressure &lt;85 mm Hg at the end of the 20-min equilibrium period were not included in the study.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="32"></a>

<p class="fulltext-TEXT fulltext-INDENT"><span class="fulltext-IT">Protocol.</span> <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF1">Figure 1</a> shows the scheme of the experimental protocols. All the hearts had a 20-min stabilization period before the drug treatment. The drug concentrations tested were 1, 3, 10, and 30 µ<span class="fulltext-IT">M.</span> Cilostazol and OPC-13015 precipitated from the solution at 100 µ<span class="fulltext-IT">M</span> after several minutes of gassing; therefore 100 µ<span class="fulltext-IT">M</span> was not studied. For each concentration, hearts were exposed to 5 min of the drug followed by a 10-min washout period. The cardiac functional measurements were performed at the end of the 5-min drug perfusion and at the end of the 10-min washout period. At both these time points, cardiac function had stabilized. Each heart was exposed to only one drug but to all the concentrations tested in a stepwise manner. Because 10 min was sufficient to wash out the previous drug effect, the drug effect is expressed as the percentage change of values before and after each drug concentration. <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#MM1">Equation (1)</a>
</p>
<!-- formatGraphic.tt2 begin -->
    </td><td class="fulltext-body-img">
    <table>
    <tbody><tr>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="FF1" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb.cgi" alt="Graphic" title="Fig. 1"></a>
          Fig. 1
       </td>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="MM1" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cMM1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(1).cgi" alt="Graphic" title="Equation 1"></a>
          Equation 1
       </td>
      <td valign="top" align="center">
       </td>
    </tr>
    </tbody></table>
<!-- formatGraphic.tt2 end -->
            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="33"></a>

<p class="fulltext-TEXT fulltext-INDENT">OPC-13015 also was evaluated in this series of experiments, because it is the only metabolite with even higher potency of PDE3 inhibition than its parent compound.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="34"></a>

<p class="fulltext-TEXT fulltext-INDENT">To examine whether the nitric oxide (NO)-guanylyl cyclase pathway plays a role in the cardiac effects of cilostazol, we studied a group of rabbit hearts treated with a potent and selective NO-sensitive guanylyl cyclase inhibitor ODQ <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#83">(27)</a>. Hearts were first perfused with 10 µ<span class="fulltext-IT">M</span> cilostazol for 5 min, followed by drug-free buffer for 10 min. Perfusion was then switched to ODQ (1 µ<span class="fulltext-IT">M</span>) for 5 min followed by 5 min of ODQ (1 µ<span class="fulltext-IT">M</span>) plus 10 µ<span class="fulltext-IT">M</span> cilostazol. The percentage changes induced by cilostazol were compared without or with ODQ.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="35"></a>

<div class="fulltext-LEVEL2">
<h5>Statistical analysis
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="36"></a>

<p class="fulltext-TEXT fulltext-INDENT">Data are presented as the percentage change from baseline (mean ± SEM). A value of p &lt; 0.05 was taken as the level of statistical significance (random-effect modeling approach, SAS). Because repeated measurements were taken from each volunteer, each rabbit or each heart, the measurements for each assay were correlated. Therefore in evaluating the treatment and concentration effects, the random-effects modeling approach was used according to Wald statistics <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#84">(28,29)</a>. In these analyses, the intercept for each subject is considered random. PROC MIXED in SAS was used to fit the random-effects models.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="37"></a>

<div class="fulltext-LEVEL1">
<h4>RESULTS
</h4>
</div>            </td></tr>
          
            
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="38"></a>

<div class="fulltext-LEVEL2">
<h5>cAMP studies
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="39"></a>

<p class="fulltext-TEXT fulltext-INDENT">The basal levels of cAMP were comparable among experiments in each group, and the averaged values were higher in human platelets (1.9 ± 0.2 pmol/10<sup class="fulltext-SP">8</sup> cells; five experiments) than those in rabbit platelets (0.3 ± 0.1 pmol/10<sup class="fulltext-SP">8</sup> cells; five experiments). Cilostazol and milrinone both significantly increased intracellular cAMP in human <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#FF2">(Fig. 2A)</a> and rabbit platelets <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF2">(Fig. 2B)</a> in a concentration-dependent manner (p &lt; 0.01 at each concentration vs. baseline value). Statistical analysis showed no significant difference between the two agents. The overall effect of cilostazol and milrinone on intracellular cAMP accumulation was greater in rabbit platelets than in human platelets.
</p>
<!-- formatGraphic.tt2 begin -->
    </td><td class="fulltext-body-img">
    <table>
    <tbody><tr>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="FF2" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF2&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(2).cgi" alt="Graphic" title="Fig. 2"></a>
          Fig. 2
       </td>
      <td valign="top" align="center">
       </td>
      <td valign="top" align="center">
       </td>
    </tr>
    </tbody></table>
<!-- formatGraphic.tt2 end -->
            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="40"></a>

<p class="fulltext-TEXT fulltext-INDENT">In rabbit cardiac myocytes, preliminary time-course studies were conducted at 5, 10, or 30 min of drug incubation. All three treatments caused similar increases in cAMP (data not shown). Thus we chose 10 min of drug incubation for a subsequent comparison study <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF2">(Fig. 2C)</a>. The basal levels of cAMP were comparable among experiments, and the averaged value was 78 ± 5.2 pmol/10<sup class="fulltext-SP">6</sup> cells. Milrinone significantly increased cAMP from baseline at each concentration (p &lt; 0.05), whereas cilostazol caused significant increases only at 10 µ<span class="fulltext-IT">M</span> and higher. Furthermore, compared with milrinone, the increases induced by cilostazol were significantly smaller at 10 µ<span class="fulltext-IT">M</span> (p &lt; 0.05) and 30 and 100 µ<span class="fulltext-IT">M</span> (p &lt; 0.005).
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="41"></a>

<p class="fulltext-TEXT fulltext-INDENT">The basal levels of cAMP were comparable among experiments in rabbit coronary smooth muscle cells, and the averaged value was 70.1 ± 4.2 pmol/10<sup class="fulltext-SP">6</sup> cells. Milrinone elevated cAMP levels at &gt;=10 µ<span class="fulltext-IT">M</span> (p &lt; 0.01 vs. baseline), as shown in <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF2">Fig. 2D</a>. However, cilostazol did not increase intracellular cAMP in any of the concentrations tested.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="42"></a>

<div class="fulltext-LEVEL2">
<h5>Platelet aggregation
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="43"></a>

<p class="fulltext-TEXT fulltext-INDENT">Consistent with the results of intracellular cAMP measurement, the potency of cilostazol and milrinone to inhibit human platelet aggregation was similar <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF3">(Fig. 3)</a>. The median inhibitory concentration (IC<sub class="fulltext-SB">50</sub>) values (obtained by sigmoidal fitting of the mean data) were 0.9 µ<span class="fulltext-IT">M</span> for cilostazol and 2 µ<span class="fulltext-IT">M</span> for milrinone.
</p>
<!-- formatGraphic.tt2 begin -->
    </td><td class="fulltext-body-img">
    <table>
    <tbody><tr>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="FF3" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF3&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(3).cgi" alt="Graphic" title="Fig. 3"></a>
          Fig. 3
       </td>
      <td valign="top" align="center">
       </td>
      <td valign="top" align="center">
       </td>
    </tr>
    </tbody></table>
<!-- formatGraphic.tt2 end -->
            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="44"></a>

<div class="fulltext-LEVEL2">
<h5>Isolated heart studies
</h5>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="45"></a>

<p class="fulltext-TEXT fulltext-INDENT">We performed vehicle control experiments in three hearts but did not observe any effect arising from any of the DMSO concentrations (maximal, 0.1%) used in our drug-treatment study. Cardiac function deterioration was &lt;10% during the 90 min of perfusion. The basal cardiac functions were comparable among three groups, as shown in <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#TT1">Table 1</a>, and the percentage changes from baseline caused by milrinone, cilostazol, and OPC-13015 are summarized in <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">Fig. 4</a>.
</p>
<!-- formatGraphic.tt2 begin -->
    </td><td class="fulltext-body-img">
    <table>
    <tbody><tr>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="TT1" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cTT1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(4).cgi" alt="Graphic" title="Table 1"></a>
          Table 1
       </td>
      <td valign="top" align="center"><a class="fulltext-image render-content-box" name="FF4" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF4&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1">
          <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(5).cgi" alt="Graphic" title="Fig. 4"></a>
          Fig. 4
       </td>
      <td valign="top" align="center">
       </td>
    </tr>
    </tbody></table>
<!-- formatGraphic.tt2 end -->
            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="46"></a>

<p class="fulltext-TEXT fulltext-INDENT"><a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">Figure 4A</a> shows the changes of LVDP. Milrinone increased LVDP at all the concentrations tested (p &lt; 0.05 vs. baseline). Cilostazol did not have a significant effect on LVDP. Milrinone also increased dp/dt (maximal values of dp/dt as an index of contractility) from baseline values (p &lt; 0.01; <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">Fig. 4B</a>). Cilostazol at 1 and 3 µ<span class="fulltext-IT">M</span> did not increase dp/dt (-2 ± -3% and 5 ± 2%, respectively). At concentrations of 10 and 30 µ<span class="fulltext-IT">M,</span> it did have a positive inotropic effect (13 ± 5% and 18 ± 6% increases, respectively; p &lt; 0.05 vs. baseline). The increases of dp/dt seen with milrinone were significantly higher than those with cilostazol at all the concentrations tested (p &lt; 0.05). There were no dose-dependent responses from OPC-13015 on LVDP and dp/dt. Although 1 µ<span class="fulltext-IT">M</span> OPC-13015 increased both LVDP and dp/dt (p &lt; 0.05 vs. basal value), as did milrinone, there was no further increase at higher concentrations. Coronary-flow changes are shown in <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">Fig. 4C</a>. Milrinone and cilostazol concentration-dependently increased coronary flow at &gt;=3 µ<span class="fulltext-IT">M</span> (p &lt; 0.01 vs. baseline), whereas OPC-13015 significantly increased coronary flow at all the concentrations tested (p &lt; 0.01 vs. baseline). There was no significant difference among the three groups at any concentration. Heart rates did not change significantly after milrinone or cilostazol perfusion, although both agents showed a slightly positive chronotropic effect <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">(Fig. 4D)</a>. The increase in heart rate seen with OPC-13015 was even less, compared with milrinone or cilostazol.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="47"></a>

<p class="fulltext-TEXT fulltext-INDENT">ODQ is a potent and selective NO-sensitive guanylyl cyclase inhibitor <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#83">(27)</a>. Treating the heart with 1 µ<span class="fulltext-IT">M</span> ODQ did not affect the percentage changes of cardiac function caused by cilostazol. In the absence of ODQ, 10 µ<span class="fulltext-IT">M</span> cilostazol caused a 22 ± 5% increase in dp/dt and 55 ± 9% increase in coronary flow (n = 5). These values are similar to those obtained in the presence of 1 µ<span class="fulltext-IT">M</span> ODQ (25 ± 3% and 59 ± 13% increases, respectively; n = 5). A potent nitric oxide synthase inhibitor, <span class="fulltext-IT">N</span><sup class="fulltext-SP">G</sup>-nitro-L-arginine (L-NNA), did not affect the cardiac effects of cilostazol either (data not shown).
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="48"></a>

<div class="fulltext-LEVEL1">
<h4>DISCUSSION
</h4>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="49"></a>

<p class="fulltext-TEXT fulltext-INDENT">Although progress has been made in surgical and non-pharmacologic interventional techniques for the management of PAOD in recent years, drug therapy is still an important noninvasive intervention to provide symptomatic relief by improving pain-free and overall walking distance <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#86">(30)</a>. Cilostazol has been used successfully to treat patients with PAOD for &gt;10 years in Japan and other Asian countries <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#57">(1-3)</a>. Cilostazol also provided efficacy for the treatment of the symptoms of intermittent claudication in several recent clinical trials in the United States and Europe <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#62">(6,7)</a>. The FDA recently approved cilostazol for such use <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#65">(9)</a>. Although the underlying mechanisms of such treatment are not fully understood, the beneficial effects may be due to the inhibition of PDE enzymes, in particular PDE3 isoforms, resulting in elevation of intracellular cAMP levels and subsequent inhibition of platelet aggregation and vasodilation. PDE3 inhibitors also enhance cardiac contractility <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#71">(15,31)</a>. The increased heart contractility and decreased peripheral resistance from PDE3 inhibitors were originally thought to be a perfect combination to treat heart failure. However, long-term use of PDE3 inhibitors in severe congestive heart failure patients has been associated with increased mortality <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#75">(19-21)</a>. Although there are no data on the effects of PDE3 inhibitors on people without severe congestive heart failure, the possible adverse cardiac effects of cilostazol are still a safety concern.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="50"></a>

<p class="fulltext-TEXT fulltext-INDENT">In this study, we compared the potency of cilostazol with that of a conventional PDE3 inhibitor, milrinone, on the elevation of intracellular cAMP levels in platelets, cardiac ventricular myocytes, and coronary artery smooth muscle cells, and on platelet and cardiac function. Consistent with their equal inhibitory potencies on PDE3 <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#88">(32)</a>, cilostazol and milrinone concentration-dependently increased intracellular cAMP in human and rabbit platelets and inhibited human platelet aggregation with similar potency. These data are consistent with those reported in the literature <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#66">(10,11,33-35)</a>.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="51"></a>

<p class="fulltext-TEXT fulltext-INDENT">We next measured intracellular cAMP levels in rabbit ventricular myocytes and cardiac contractility, heart rate, and coronary flow in isolated rabbit hearts. Our results show that cilostazol did not increase cAMP as much as milrinone did. This is in agreement with the effects on cardiac contractility: whereas milrinone concentration-dependently increased cardiac contractility, the overall effect from cilostazol was significantly smaller. These results suggest that cilostazol is quite different from milrinone, and the contractility changes from cilostazol cannot be solely explained by PDE3 inhibition because the potencies of cilostazol and milrinone on PDE3 are very similar <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#88">(32)</a>.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="52"></a>

<p class="fulltext-TEXT fulltext-INDENT">PDE3 inhibitors also have profound vasodilatory effects <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#92">(36)</a>. To our surprise, although cilostazol increased coronary flow as potently as milrinone in our isolated rabbit heart model, it did not elevate intracellular cAMP levels in rabbit coronary smooth muscle cells. In the cAMP measurement study, we used 10 min for drug treatment (the same as for myocytes). It is unlikely that the effect of cilostazol on cAMP levels is delayed because we saw the increase of coronary flow within 1 min after the start of cilostazol perfusion. There were other studies on the effect of cilostazol on vascular smooth muscle cells. Ikeda et al. <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#93">(37)</a> showed that treatment with 10 µ<span class="fulltext-IT">M</span> cilostazol for 24 h increases cAMP in rat aorta smooth muscle cells. However, the marked difference of drug-exposure time makes it impossible to compare that study directly with ours. Consistent with our results, Tanaka et al. <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#94">(38)</a> did not see an increase of intracellular cAMP by 12-min incubation of 10 µ<span class="fulltext-IT">M</span> cilostazol with rabbit aortic artery smooth muscle cells. When Lindgren et al. <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#90">(34)</a> compared OPC-3911 (a PDE3 inhibitor structurally similar to cilostazol) with milrinone in platelet and rat aorta, they obtained results similar to what we found. In platelets, OPC-3911 and milrinone increased cAMP levels, but in the rat aorta, the increase was significant only for milrinone despite the similar potency in inhibition of PDE3 <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#95">(39)</a>. Nevertheless, OPC-3911 and milrinone had similar relaxant profiles in human and rat coronary and renal arteries <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#96">(40)</a>. We hypothesize that the poor correlation between cAMP level elevation and flow increase seen with cilostazol may reflect the compartmentation of cAMP in smooth muscle cells <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#92">(36)</a>, and the whole-cell cAMP measurement may not readily detect the localized cAMP changes.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="53"></a>

<p class="fulltext-TEXT fulltext-INDENT">Considering that cilostazol also inhibits PDE5 (although to a lesser extent than PDE3), which exists in vascular smooth muscle cells, we examined whether NO and cGMP were involved in the flow increase caused by cilostazol. Our data show that neither NO synthase inhibitor L-NNA nor NO-sensitive guanylyl cyclase inhibitor ODQ affected the cilostazol-induced flow increase. L-NNA and ODQ did not alter the effects of cilostazol on cardiac contractility. These data suggest that the NO pathway does not account for the differences observed in this study between cilostazol and milrinone.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="54"></a>

<p class="fulltext-TEXT fulltext-INDENT">Of the several metabolites of cilostazol in vivo, the plasma concentration of OPC-13015 reaches as much as 20% of the parent compound, but it inhibits PDE3 with about sevenfold higher potency <a class="fulltext-RA" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#80">(24)</a>. Thus OPC-13015 may account for a substantial amount of biologic activity from cilostazol; therefore we studied its effect on cardiac function in our isolated rabbit heart model. <a class="fulltext-GX" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#FF4">Figure 4</a> shows that the cardiac effect of OPC-13015 is similar to that of cilostazol: both have significantly less impact on LVDP and contractility than does milrinone. In our preliminary study, the cAMP-elevating abilities of OPC-13015 and cilostazol were similar in isolated rabbit ventricular myocytes (data not shown), consistent with our cardiac contractility data. The effects on coronary flows among these three compounds are not different. OPC-13015 has almost no effect on heart rate. These data show that, although OPC-13015 has higher inhibitory effect on PDE3, its effect on cardiac function is not greater than that of cilostazol. This further supports the idea that the pharmacodynamic effects of PDE3 inhibitors may not all be alike. Although the cardiovascular effects from milrinone parallel PDE3 inhibition, there are large differences for cilostazol between PDE3 inhibition and its effect on cardiac cells. Future studies are needed to explain such differences and may shed light on the efficacy of cilostazol in the treatment of patients with PAOD.
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="55"></a>

<p class="fulltext-TEXT fulltext-INDENT">In summary, we have shown that cilostazol increases intracellular cAMP in platelets and inhibits platelet aggregation as potently as does milrinone. However, the increase of intracellular cAMP and related cardiac functional changes from cilostazol are much less compared with those of milrinone. The data presented herein are consistent with the beneficial and safe outcomes in the treatment of patients with intermittent claudication and indicate that the biologic activities of cilostazol cannot be explained by PDE3 inhibition alone.
</p>            </td></tr>
          
                </tbody></table><div class="fulltext-body-backtotop">                     <a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
            </div><table><tbody><tr><td class="fulltext-body-paragraph"><a name="56"></a>

<div class="fulltext-LEVEL1">
<h4>REFERENCES
</h4>
</div>            </td></tr>
          
            
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="57"></a>

<p class="fulltext-REFERENCES">1. Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. <span class="fulltext-IT">Arzneimittelforschung</span> 1985;35:1198-200. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1198_yasuda_arteriosclerosis_%7c00005344-199910000-00004%23xpointer%28id%28R1-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=57&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1198_yasuda_arteriosclerosis_%7c00005344-199910000-00004%23xpointer%28id%28R1-4%29%29%7c60%7c%7covftdb%7c&amp;P=57&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="58"></a><a name="RF1"></a>

<p class="fulltext-REFERENCES">2. Kamiya T, Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities. <span class="fulltext-IT">Arzneimittelforschung</span> 1985;35:1201-3. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1201_kamiya_antithrombotic_%7c00005344-199910000-00004%23xpointer%28id%28R2-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=58&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1201_kamiya_antithrombotic_%7c00005344-199910000-00004%23xpointer%28id%28R2-4%29%29%7c60%7c%7covftdb%7c&amp;P=58&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="59"></a><a name="RF2"></a>

<p class="fulltext-REFERENCES">3. Ohashi S, Iwatani M, Hyakuna Y, et al. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. <span class="fulltext-IT">Arzneimittelforschung</span> 1985;35:1203-8. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1203_ohashi_antithrombotic_%7c00005344-199910000-00004%23xpointer%28id%28R3-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=59&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1203_ohashi_antithrombotic_%7c00005344-199910000-00004%23xpointer%28id%28R3-4%29%29%7c60%7c%7covftdb%7c&amp;P=59&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="60"></a><a name="RF3"></a>

<p class="fulltext-REFERENCES">4. Hiatt WR. Current and future drug therapies for claudication. <span class="fulltext-IT">Vasc Med</span> 1997;2:257-62. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00115509_1997_2_257_hiatt_claudication_%7c00005344-199910000-00004%23xpointer%28id%28R4-4%29%29%7c11302722%7c%7covftdb%7c00115509-199702030-00016&amp;P=60&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00115509_1997_2_257_hiatt_claudication_%7c00005344-199910000-00004%23xpointer%28id%28R4-4%29%29%7c60%7c%7covftdb%7c00115509-199702030-00016&amp;P=60&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="61"></a><a name="RF4"></a>

<p class="fulltext-REFERENCES">5. Regensteiner J, Stiener J, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. <span class="fulltext-IT">J Vasc Surg</span> 1996;23:104-15. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1996_23_104_regensteiner_functional_%7c00005344-199910000-00004%23xpointer%28id%28R5-4%29%29%7c11302722%7c%7covftdb%7c00005397-199601000-00013&amp;P=61&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1996_23_104_regensteiner_functional_%7c00005344-199910000-00004%23xpointer%28id%28R5-4%29%29%7c25%7c%7covftdb%7c00005397-199601000-00013&amp;P=61&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Buy Now</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1996_23_104_regensteiner_functional_%7c00005344-199910000-00004%23xpointer%28id%28R5-4%29%29%7c60%7c%7covftdb%7c00005397-199601000-00013&amp;P=61&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="62"></a><a name="RF5"></a>

<p class="fulltext-REFERENCES">6. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. <span class="fulltext-IT">J Vasc Surg</span> 1998;27:267-74. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1998_27_267_money_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R6-4%29%29%7c11302722%7c%7covftdb%7c00005397-199802000-00009&amp;P=62&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1998_27_267_money_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R6-4%29%29%7c25%7c%7covftdb%7c00005397-199802000-00009&amp;P=62&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Buy Now</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005397_1998_27_267_money_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R6-4%29%29%7c60%7c%7covftdb%7c00005397-199802000-00009&amp;P=62&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="63"></a><a name="RF6"></a>

<p class="fulltext-REFERENCES">7. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. <span class="fulltext-IT">Circulation</span> 1998;98:678-86. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_98_678_dawson_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R7-4%29%29%7c10%7c%7covftdb%7c00003017-199808180-00011&amp;P=63&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_98_678_dawson_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R7-4%29%29%7c11302722%7c%7covftdb%7c00003017-199808180-00011&amp;P=63&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_98_678_dawson_intermittent_%7c00005344-199910000-00004%23xpointer%28id%28R7-4%29%29%7c60%7c%7covftdb%7c00003017-199808180-00011&amp;P=63&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="64"></a><a name="RF7"></a>

<p class="fulltext-REFERENCES">8. Elam MB, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. <span class="fulltext-IT">Arterioscler Thromb Vasc Biol</span> 1998;18:1942-7. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00043605_1998_18_1942_elam_antiplatelet_%7c00005344-199910000-00004%23xpointer%28id%28R8-4%29%29%7c10%7c%7covftdb%7c00043605-199812000-00016&amp;P=64&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00043605_1998_18_1942_elam_antiplatelet_%7c00005344-199910000-00004%23xpointer%28id%28R8-4%29%29%7c11302722%7c%7covftdb%7c00043605-199812000-00016&amp;P=64&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00043605_1998_18_1942_elam_antiplatelet_%7c00005344-199910000-00004%23xpointer%28id%28R8-4%29%29%7c60%7c%7covftdb%7c00043605-199812000-00016&amp;P=64&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="65"></a><a name="RF8"></a>

<p class="fulltext-REFERENCES">9. Food and Drug Administration. <span class="fulltext-IT">FDA approval of cilostazol.</span> Washington, DC: FDA, 1999. <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="66"></a><a name="RF9"></a>

<p class="fulltext-REFERENCES">10. Uehara S, Hirayama A. Effects of cilostazol on platelet function. <span class="fulltext-IT">Arzneimittelforschung</span> 1989;39:1531-4. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1989_39_1531_uehara_cilostazol_%7c00005344-199910000-00004%23xpointer%28id%28R10-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=66&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1989_39_1531_uehara_cilostazol_%7c00005344-199910000-00004%23xpointer%28id%28R10-4%29%29%7c60%7c%7covftdb%7c&amp;P=66&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="67"></a><a name="RF10"></a>

<p class="fulltext-REFERENCES">11. Tani T, Sakurai K, Kimura Y, et al. Pharmacological manipulation of tissue cyclic AMP by inhibitors: effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells. <span class="fulltext-IT">Adv Second Messenger Phosphoprotein Res</span> 1992;25:215-27. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002198_1992_25_215_tani_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R11-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=67&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002198_1992_25_215_tani_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R11-4%29%29%7c60%7c%7covftdb%7c&amp;P=67&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="68"></a><a name="RF11"></a>

<p class="fulltext-REFERENCES">12. Sheth SB, Colman RW. Regulatory and catalytic domains of platelet cAMP phosphodiesterases: targets for drug design. <span class="fulltext-IT">Semin Hematol</span> 1995;32:110-9. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00007545_1995_32_110_sheth_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R12-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=68&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00007545_1995_32_110_sheth_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R12-4%29%29%7c60%7c%7covftdb%7c&amp;P=68&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="69"></a><a name="RF12"></a>

<p class="fulltext-REFERENCES">13. Nagaoka T, Shirakawa T, Kasuya J, et al. Cyclic nucleotide PDE-3: quantitation of PDE-3A and -3B mRNAs in rat tissues by RNase protection assay. <span class="fulltext-IT">Cell Biochem Biophys</span> 1998;29:49-66. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00063476_1998_29_49_nagaoka_quantitation_%7c00005344-199910000-00004%23xpointer%28id%28R13-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=69&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00063476_1998_29_49_nagaoka_quantitation_%7c00005344-199910000-00004%23xpointer%28id%28R13-4%29%29%7c60%7c%7covftdb%7c&amp;P=69&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="70"></a><a name="RF13"></a>

<p class="fulltext-REFERENCES">14. Movsesian MA, Komas N, Krall J, et al. Expression and activity of low Km, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle. <span class="fulltext-IT">Biochem Biophys Res Commun</span> 1996;225:1058-62. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00001002_1996_225_1058_movsesian_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R14-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=70&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00001002_1996_225_1058_movsesian_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R14-4%29%29%7c60%7c%7covftdb%7c&amp;P=70&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="71"></a><a name="RF14"></a>

<p class="fulltext-REFERENCES">15. Manganiello VC, Murata T, Taira M, et al. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. <span class="fulltext-IT">Arch Biochem Biophys</span> 1995;322:1-13. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000728_1995_322_1_manganiello_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R15-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=71&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000728_1995_322_1_manganiello_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R15-4%29%29%7c60%7c%7covftdb%7c&amp;P=71&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="72"></a><a name="RF15"></a>

<p class="fulltext-REFERENCES">16. Boger JE, DeLuca SL, Watkins DF, et al. Infusion therapy with milrinone in the home care setting for patients who have advanced heart failure. <span class="fulltext-IT">J Intraven Nurs</span> 1997;20:148-54. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005160_1997_20_148_boger_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R16-4%29%29%7c10%7c%7covftdb%7c&amp;P=72&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005160_1997_20_148_boger_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R16-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=72&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005160_1997_20_148_boger_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R16-4%29%29%7c60%7c%7covftdb%7c&amp;P=72&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="73"></a><a name="RF16"></a>

<p class="fulltext-REFERENCES">17. Mehra MR, Ventura HO, Kapoor C, et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. <span class="fulltext-IT">Am J Cardiol</span> 1997;80:61-4. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000416_1997_80_61_mehra_intravenous_%7c00005344-199910000-00004%23xpointer%28id%28R17-4%29%29%7c11302722%7c%7covftdb%7c00000416-199707010-00012&amp;P=73&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000416_1997_80_61_mehra_intravenous_%7c00005344-199910000-00004%23xpointer%28id%28R17-4%29%29%7c60%7c%7covftdb%7c00000416-199707010-00012&amp;P=73&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="74"></a><a name="RF17"></a>

<p class="fulltext-REFERENCES">18. Lynch JJJ, Uprichard AC, Frye JW, et al. Effects of the positive inotropic agents milrinone and pimobendan on the development of lethal ischemic arrhythmias in conscious dogs with recent myocardial infarction. <span class="fulltext-IT">J Cardiovasc Pharmacol</span> 1989;14:585-97. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005344_1989_14_585_lynch_development_%7c00005344-199910000-00004%23xpointer%28id%28R18-4%29%29%7c11302722%7c%7covftdb%7c00005344-198910000-00010&amp;P=74&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005344_1989_14_585_lynch_development_%7c00005344-199910000-00004%23xpointer%28id%28R18-4%29%29%7c25%7c%7covftdb%7c00005344-198910000-00010&amp;P=74&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Buy Now</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005344_1989_14_585_lynch_development_%7c00005344-199910000-00004%23xpointer%28id%28R18-4%29%29%7c60%7c%7covftdb%7c00005344-198910000-00010&amp;P=74&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="75"></a><a name="RF18"></a>

<p class="fulltext-REFERENCES">19. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. <span class="fulltext-IT">N Engl J Med</span> 1991;325:1468-75. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00006024_1991_325_1468_packer_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R19-4%29%29%7c11302722%7c%7covftdb%7c00006024-199111210-00003&amp;P=75&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00006024_1991_325_1468_packer_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R19-4%29%29%7c25%7c%7covftdb%7c00006024-199111210-00003&amp;P=75&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Buy Now</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00006024_1991_325_1468_packer_milrinone_%7c00005344-199910000-00004%23xpointer%28id%28R19-4%29%29%7c60%7c%7covftdb%7c00006024-199111210-00003&amp;P=75&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="76"></a><a name="RF19"></a>

<p class="fulltext-REFERENCES">20. Packer M. Treatment of chronic heart failure. <span class="fulltext-IT">Lancet</span> 1992;340:92-5. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005531_1992_340_92_packer_treatment_%7c00005344-199910000-00004%23xpointer%28id%28R20-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=76&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005531_1992_340_92_packer_treatment_%7c00005344-199910000-00004%23xpointer%28id%28R20-4%29%29%7c60%7c%7covftdb%7c&amp;P=76&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="77"></a><a name="RF20"></a>

<p class="fulltext-REFERENCES">21. Thadani U, Roden DM. FDA panel report: January 1998. <span class="fulltext-IT">Circulation</span> 1998;97:2295-6. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_97_2295_thadani_january_%7c00005344-199910000-00004%23xpointer%28id%28R21-4%29%29%7c10%7c%7covftdb%7c&amp;P=77&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_97_2295_thadani_january_%7c00005344-199910000-00004%23xpointer%28id%28R21-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=77&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003017_1998_97_2295_thadani_january_%7c00005344-199910000-00004%23xpointer%28id%28R21-4%29%29%7c60%7c%7covftdb%7c&amp;P=77&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="78"></a><a name="RF21"></a>

<p class="fulltext-REFERENCES">22. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. <span class="fulltext-IT">Vasc Med</span> 1997;2:221-6. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00115509_1997_2_221_criqui_epidemiology_%7c00005344-199910000-00004%23xpointer%28id%28R22-4%29%29%7c11302722%7c%7covftdb%7c00115509-199702030-00010&amp;P=78&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00115509_1997_2_221_criqui_epidemiology_%7c00005344-199910000-00004%23xpointer%28id%28R22-4%29%29%7c60%7c%7covftdb%7c00115509-199702030-00010&amp;P=78&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="79"></a><a name="RF22"></a>

<p class="fulltext-REFERENCES">23. Brevetti G, Martone VD, Perna S, et al. Intermittent claudication and risk of cardiovascular events. <span class="fulltext-IT">Angiology</span> 1998;49:843-8. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000550_1998_49_843_brevetti_cardiovascular_%7c00005344-199910000-00004%23xpointer%28id%28R23-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=79&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000550_1998_49_843_brevetti_cardiovascular_%7c00005344-199910000-00004%23xpointer%28id%28R23-4%29%29%7c60%7c%7covftdb%7c&amp;P=79&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#14">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="80"></a><a name="RF23"></a>

<p class="fulltext-REFERENCES">24. Otsuka America Pharmaceutical, Inc. <span class="fulltext-IT">NDA 20-863: cilostazol.</span> Rockville: Otsuka America Pharmaceutical, 1997. <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#15">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="81"></a><a name="RF24"></a>

<p class="fulltext-REFERENCES">25. Liu Y, Gao WD, O'Rourke B, et al. Synergistic modulation of ATP-sensitive K<sup class="fulltext-SP">+</sup> currents by protein kinase C and adenosine: implications for ischemic preconditioning. <span class="fulltext-IT">Circ Res</span> 1996;78:443-54. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1996_78_443_liu_preconditioning_%7c00005344-199910000-00004%23xpointer%28id%28R25-4%29%29%7c10%7c%7covftdb%7c00003012-199603000-00012&amp;P=81&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1996_78_443_liu_preconditioning_%7c00005344-199910000-00004%23xpointer%28id%28R25-4%29%29%7c11302722%7c%7covftdb%7c00003012-199603000-00012&amp;P=81&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1996_78_443_liu_preconditioning_%7c00005344-199910000-00004%23xpointer%28id%28R25-4%29%29%7c60%7c%7covftdb%7c00003012-199603000-00012&amp;P=81&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#22">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="82"></a><a name="RF25"></a>

<p class="fulltext-REFERENCES">26. Yasunari K, Kohno M, Kano H, et al. Mechanisms of action of troglitazone in the prevention of high glucose-induced migration and proliferation of cultured coronary smooth muscle cells. <span class="fulltext-IT">Circ Res</span> 1997;81:953-62. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1997_81_953_yasunari_proliferation_%7c00005344-199910000-00004%23xpointer%28id%28R26-4%29%29%7c10%7c%7covftdb%7c&amp;P=82&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Ovid Full Text</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1997_81_953_yasunari_proliferation_%7c00005344-199910000-00004%23xpointer%28id%28R26-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=82&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003012_1997_81_953_yasunari_proliferation_%7c00005344-199910000-00004%23xpointer%28id%28R26-4%29%29%7c60%7c%7covftdb%7c&amp;P=82&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#23">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="83"></a><a name="RF26"></a>

<p class="fulltext-REFERENCES">27. Garthwaite J, Southam E, Boulton CL, et al. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. <span class="fulltext-IT">Mol Pharmacol</span> 1995;48:184-8. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005952_1995_48_184_garthwaite_4oxadiazolo4_%7c00005344-199910000-00004%23xpointer%28id%28R27-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=83&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00005952_1995_48_184_garthwaite_4oxadiazolo4_%7c00005344-199910000-00004%23xpointer%28id%28R27-4%29%29%7c60%7c%7covftdb%7c&amp;P=83&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#34">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="84"></a><a name="RF27"></a>

<p class="fulltext-REFERENCES">28. Laird NM, Ware JH. Random effects models for longitudinal data. <span class="fulltext-IT">Biometrics</span> 1982;38:963-74. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00001726_1982_38_963_laird_longitudinal_%7c00005344-199910000-00004%23xpointer%28id%28R28-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=84&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00001726_1982_38_963_laird_longitudinal_%7c00005344-199910000-00004%23xpointer%28id%28R28-4%29%29%7c60%7c%7covftdb%7c&amp;P=84&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#36">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="85"></a><a name="RF28"></a>

<p class="fulltext-REFERENCES">29. Laird NM, Lange N, Stram D. Maximum likelihood computations with repeated measures: application of the EM algorithm. <span class="fulltext-IT">J Am Stat Assoc</span> 1987;82:87-105. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00009683_1987_82_87_laird_computations_%7c00005344-199910000-00004%23xpointer%28id%28R29-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=85&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#36">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="86"></a><a name="RF29"></a>

<p class="fulltext-REFERENCES">30. Darvin H, King T. Lower extremity arterial occlusive disease. <span class="fulltext-IT">Clin Podiatr Med Surg</span> 1992;9:69-77. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002803_1992_9_69_darvin_extremity_%7c00005344-199910000-00004%23xpointer%28id%28R30-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=86&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002803_1992_9_69_darvin_extremity_%7c00005344-199910000-00004%23xpointer%28id%28R30-4%29%29%7c60%7c%7covftdb%7c&amp;P=86&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#49">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="87"></a><a name="RF30"></a>

<p class="fulltext-REFERENCES">31. Manganiello VC, Taira M, Degerman E, et al. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). <span class="fulltext-IT">Cell Signal</span> 1995;7:445-55. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002276_1995_7_445_manganiello_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R31-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=87&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00002276_1995_7_445_manganiello_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R31-4%29%29%7c60%7c%7covftdb%7c&amp;P=87&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#49">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="88"></a><a name="RF31"></a>

<p class="fulltext-REFERENCES">32. Inoue Y, Tochizawa S, Toga K, Tachibana K, Nagamoto M, Sudo T. <span class="fulltext-IT">Effects of OPC-33509 and references on activity of cyclic nucleotide phosphodiesterase type 1, 2, 3A, 3B, 4, 5, and 7 in vitro.</span> Tokushima, Japan: Otsuka Pharmaceutical Co., Ltd. In-House Report 01152, 1997. <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#50">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="89"></a><a name="RF32"></a>

<p class="fulltext-REFERENCES">33. Kimura Y, Tani T, Kanbe T, et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. <span class="fulltext-IT">Arzneimittelforschung</span> 1985;35:1144-9. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1144_kimura_experimental_%7c00005344-199910000-00004%23xpointer%28id%28R33-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=89&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000892_1985_35_1144_kimura_experimental_%7c00005344-199910000-00004%23xpointer%28id%28R33-4%29%29%7c60%7c%7covftdb%7c&amp;P=89&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#50">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="90"></a><a name="RF33"></a>

<p class="fulltext-REFERENCES">34. Lindgren SH, Andersson TL, Vinge E, et al. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. <span class="fulltext-IT">Acta Physiol Scand</span> 1990;140:209-19. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000191_1990_140_209_lindgren_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R34-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=90&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000191_1990_140_209_lindgren_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R34-4%29%29%7c60%7c%7covftdb%7c&amp;P=90&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#50">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="91"></a><a name="RF34"></a>

<p class="fulltext-REFERENCES">35. Pattison A, Astley N, Eason CT, et al. A comparison of the effects of three positive inotropic agents (amrinone, milrinone and medorinone) on platelet aggregation in human whole blood. <span class="fulltext-IT">Thromb Res</span> 1990;57:909-18. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00007788_1990_57_909_pattison_aggregation_%7c00005344-199910000-00004%23xpointer%28id%28R35-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=91&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00007788_1990_57_909_pattison_aggregation_%7c00005344-199910000-00004%23xpointer%28id%28R35-4%29%29%7c60%7c%7covftdb%7c&amp;P=91&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#50">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="92"></a><a name="RF35"></a>

<p class="fulltext-REFERENCES">36. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. <span class="fulltext-IT">Annu Rev Pharmacol Toxicol</span> 1996;36:403-27. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000685_1996_36_403_polson_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R36-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=92&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000685_1996_36_403_polson_phosphodiesterases_%7c00005344-199910000-00004%23xpointer%28id%28R36-4%29%29%7c60%7c%7covftdb%7c&amp;P=92&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#52">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="93"></a><a name="RF36"></a>

<p class="fulltext-REFERENCES">37. Ikeda U, Ikeda M, Kano S, et al. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. <span class="fulltext-IT">Eur J Pharmacol</span> 1996;314:197-202. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003656_1996_314_197_ikeda_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R37-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=93&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00003656_1996_314_197_ikeda_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R37-4%29%29%7c60%7c%7covftdb%7c&amp;P=93&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#52">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="94"></a><a name="RF37"></a>

<p class="fulltext-REFERENCES">38. Tanaka T, Ishikawa T, Hagiwara M, et al. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. <span class="fulltext-IT">Pharmacology</span> 1988;36:313-20. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00006495_1988_36_313_tanaka_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R38-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=94&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00006495_1988_36_313_tanaka_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R38-4%29%29%7c60%7c%7covftdb%7c&amp;P=94&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#52">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="95"></a><a name="RF38"></a>

<p class="fulltext-REFERENCES">39. Komas N, Movsesian M, Kedev S, et al. cGMP-inhibited phosphodiesterase (PDE3). In: Schudt C, Dent G, Rabe KF, eds. <span class="fulltext-IT">Phosphodiesterase inhibitors.</span> San Diego: Academic Press, 1996:89-102. <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#52">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="96"></a><a name="RF39"></a>

<p class="fulltext-REFERENCES">40. Lindgren S, Andersson KE. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. <span class="fulltext-IT">Acta Physiol Scand</span> 1991;142:77-82. <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000191_1991_142_77_lindgren_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R40-4%29%29%7c11302722%7c%7covftdb%7c&amp;P=96&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Getit</a> <a class="fulltext-SL" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?Link+Set+Ref=00005344-199910000-00004|00000191_1991_142_77_lindgren_phosphodiesterase_%7c00005344-199910000-00004%23xpointer%28id%28R40-4%29%29%7c60%7c%7covftdb%7c&amp;P=96&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Bibliographic Links</a> <a class="fulltext-BK" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#52">[Context Link]</a>
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="97"></a>

<p class="fulltext-TEXT fulltext-INDENT">Key Words: Cilostazol; Milrinone; OPC-13015; Phosphodiesterase; Platelet; Heart; Ventricular myocytes
</p>            </td></tr>
          
                </tbody></table><table><tbody><tr><td class="fulltext-body-paragraph"><a name="98"></a>

<hr class="fulltext-LINESOLID"><br>
            </td></tr>
          
 <tr>
  <td id="fulltext-image-gallery" colspan="2">
   <div id="fulltext-image-gallery-header">
    <a name="image-gallery">
    IMAGE GALLERY
   </a></div><!-- image_gallery.tt2 begin --><a name="image-gallery">

</a><div id="fulltext-image-gallery-sub-header"><a name="image-gallery">
    </a><div id="fulltext-image-gallery-select-all"><a name="image-gallery">
        </a><a class="tlink select-all " href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Full+Text=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;image_gallery_select=selectall&amp;resultset=S.sh.22%7c1">Select All</a>
        <a class="tlink unselect-all hide" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Full+Text=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;image_gallery_select=unselectall&amp;resultset=S.sh.22%7c1">Unselect All</a>
    </div>
    <div id="fulltext-image-gallery-export-link">
        <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/export_to_powerpoint.gif">
        <input id="export-selected-images-to-powerpoint" type="submit" name="Export PowerPoint" class="transparent-button" value="Export Selected to PowerPoint">
    </div>
</div>
<div id="image-gallery-none-selected-error" class="error hide">One of more images must be select in order to export to PowerPoint.</div>
<table> <tbody><tr>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(6).cgi" alt="Fig. 1" title="Fig. 1"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="FF1|1" name="image-select">
</span>Fig. 1</td>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cMM1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(7).cgi" alt="Equation 1" title="Equation 1"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="MM1|2" name="image-select">
</span>Equation 1</td>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF2&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(8).cgi" alt="Fig. 2" title="Fig. 2"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="FF2|3" name="image-select">
</span>Fig. 2</td>
</tr> <tr>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF3&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(9).cgi" alt="Fig. 3" title="Fig. 3"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="FF3|4" name="image-select">
</span>Fig. 3</td>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cTT1&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(10).cgi" alt="Table 1" title="Table 1"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="TT1|5" name="image-select">
</span>Table 1</td>
<td><a class="fulltext-image render-content-box" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;View+Image=00005344-199910000-00004%7cFF4&amp;D=ovft&amp;width=700&amp;height=400&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;resultset=S.sh.22%7c1"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ovidweb(11).cgi" alt="Fig. 4" title="Fig. 4"></a>
<span class="image-gallery-checkbox-container" id="image-gallery-checkbox-container">
    <input class="image-gallery-checkbox" type="checkbox" value="FF4|6" name="image-select">
</span>Fig. 4</td>
</tr></tbody></table>
<a class="tlink fulltext-body-backtotop-link" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#toc">Back to Top</a>
<!-- image_gallery.tt2 end -->

  </td>
 </tr>
</tbody></table>


<!-- body.tt2 end -->

<div class="fulltext-navbar">



<span class="fulltext-navbar-toclinks">


    <a class="tlink fulltext-navbar-links-prev" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Full+Text+Link=S.sh.22.24%7c3%7csl_10%7c80%7c2" title="Direct Block of Ca2+ Channels by Calmidazolium in Cultured Vascular Smooth Muscle Cells.">
       &lt; Previous Article
    </a>



    <a class="tlink fulltext-navbar-links-toc" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;TOC=S.sh.22.24%7c4%7c60">Table of Contents</a>



    <a class="tlink fulltext-navbar-links-next" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Full+Text+Link=S.sh.22.24%7c5%7csl_10%7c80%7c2" title="Modulation of Adrenergic Receptors During Left Ventricular Hypertrophy Development and After Regression by Captopril.">Next Article &gt;</a>


</span>




</div>
  </div></td>
  <td id="fulltext-right">
<div id="fulltext-controlbox">


<div class="fulltext-controlbox-section">
 <h2>Tools</h2>


  
  
     <div class="fulltext-link" id="fulltext-link-compref">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/compref.gif">
             
             <a class="tlink " id="compref" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Complete+Reference=S.sh.22%7c1%7c1">Complete Reference
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-abstract">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/abstract.gif">
             
             <a class="tlink " id="abstract" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Abstract=S.sh.22%7c1%7c1">Abstract Reference
             
             
             </a>
          
       
     
   </div>

  
     <div class="horizontal-gap-bar"> </div>
  
  
  
  
     <div class="fulltext-link" id="fulltext-link-ftprint">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ftprint.gif">
             
             <a class="tlink " id="ftprint" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;ftdoc=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Print+Preview=1">Print Preview
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-email-jumpstart">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/email_jumpstart.gif">
             
                  
                <span id="email" title="Email Jumpstart">
                  <a class="tlink" target="_blank" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Save+As+Jumpstart=Fulltext%7c%26PAGE%3dfulltext%26AN%3d00005344-199910000-00004%26LSLINK%3d80%26D%3dovft">Email Jumpstart
                </a></span><a class="tlink" target="_blank" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Save+As+Jumpstart=Fulltext%7c%26PAGE%3dfulltext%26AN%3d00005344-199910000-00004%26LSLINK%3d80%26D%3dovft">
                
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-email-jumpstart">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/email_jumpstart.gif">
             
                
                <span id="pdf-js-email" title="Email PDF Jumpstart">
                  <a class="tlink" target="_blank" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Save+As+Jumpstart=Fulltext%7c%26PAGE%3dfulltext%26AN%3d00005344-199910000-00004%26D%3dovft%26PDF%3dy">Email PDF Jumpstart
                </a></span><a class="tlink" target="_blank" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Save+As+Jumpstart=Fulltext%7c%26PAGE%3dfulltext%26AN%3d00005344-199910000-00004%26D%3dovft%26PDF%3dy">
                
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-ftemail">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ftemail.gif">
             
             <a class="tlink " id="ftemail" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;ftdoc=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Email+Article=1">Email Article Text
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-ftsave">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/ftsave.gif">
             
             <a class="tlink " id="ftsave" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;ftdoc=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Save+Article=1">Save Article Text
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-add-to-my-projects">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/add_to_my_projects.gif">
             
             <a class="tlink render-form" id="add-to-my-projects" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;FormProcessor=item__add&amp;InputArgs=form_name%3aitem__add%7cinterface_origin%3afh%7ckeep_selection%3aY%7cdisplay_type%3aLink+Set%7cdlname%3aS.sh.22%7cstart%3a1%7ccount%3asl_10%7cindex%3a1" input_args="form_name:item__add|interface_origin:fh|keep_selection:Y|display_type:Link Set|dlname:S.sh.22|start:1|count:sl_10|index:1">Add to My Projects
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-export-to-powerpoint">
     
                 
             <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/export_to_powerpoint.gif">
             
             <a class="tlink " id="export-to-powerpoint" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Export+PowerPoint=add&amp;an=00005344-199910000-00004&amp;resultset=S.sh.22%7c1&amp;image-select=FF1%7c1&amp;image-select=MM1%7c2&amp;image-select=FF2%7c3&amp;image-select=FF3%7c4&amp;image-select=TT1%7c5&amp;image-select=FF4%7c6">Export All Images to PowerPoint
             
             
             </a>
          
       
     
   </div>

  
  
     <div class="fulltext-link" id="fulltext-link-">
     
       <span class="annotate-pin-login" title="Annotations"><a id="annotate_link_1" class="booklist-annotate-link-pin-login" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#" onclick="javascript:annotation_pin_login_redirect(&#39;ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Full+Text=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Annotate+Personal+Account+Page=1&#39;);"><img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/new_no_annotation.gif" alt="Annotate Icon" title="Annotations"> Annotate</a><span type="hidden" id="bookanno_returnurl" value="ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Full+Text=L%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Annotate+Personal+Account+Page=1"></span></span>
     
   </div>




    <div class="horizontal-gap-bar"> </div>
    
       <div class="fulltext-link">
         <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/find_citing.gif">
         <a class="tlink" id="fulltext-link-find-citing" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Cited+By+Articles=S.sh.22%7c1&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Find Citing Articles</a>
       </div>
    
       <div class="fulltext-link">
         <img src="./Ovid_ Comparison of the Effects of Cilostazol and Milrinone on Intracellular cAMP Levels and Cellular Function in Platelets and Cardiac Cells._files/find_similar.gif">
         <a class="tlink" id="fulltext-link-find-similar" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Find+Similar=1%7c1&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">Find Similar</a>
       </div>
    


        <div class="horizontal-gap-bar"> </div>
        
        
          
        
        
          
            <div class="fulltext-link">
              <a class="tlink" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;Full+Text=R%7c00005344-199910000-00004%7caboutjournal&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004">About this Journal</a>
            </div>
          
                              <div class="fulltext-link">
              <a class="tlink" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Link+Set=S.sh.22%7c1%7csl_130">Request Permissions</a>
            </div>
                      <div class="fulltext-link">
              <a class="tlink" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?&amp;S=LKEAFPCDGPDDLONENCGKKBGCDDMIAA00&amp;WebLinkReturn=Full+Text%3dL%7cS.sh.22.23%7c0%7c00005344-199910000-00004&amp;Link+Set=S.sh.22%7c1%7csl_11302722">Getit</a>
            </div>
                  


<div class="jb-email-jumpstart-popup">
    <div class="jb-popup-header">Email Jumpstart</div>

    <div class="jb-jumpstart-url">
        <span id="pdf_html_jsurl" class="jumpstart-url"><b>Your Jumpstart URL is:</b><br><jsurl>http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;AN=00005344-199910000-00004&amp;LSLINK=80&amp;D=ovft</jsurl></span>
        <span id="pdf_jsurl" class="jumpstart-url"><b>Your Jumpstart URL is:</b><br><jsurl>http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;CSC=Y&amp;NEWS=N&amp;PAGE=fulltext&amp;AN=00005344-199910000-00004&amp;D=ovft&amp;PDF=y</jsurl></span>
    </div>

    <div class="jb-popup-content">Please enter the email address that you wish to send the jumpstart to.</div>
    <div class="error hide">The email address must look like <i>user@domain</i>.</div>
    <div class="jb-popup-option">
          <span class="jb-popup-label"><label for="searchname">Email</label></span>
          <span class="jb-popup-value">
                <input type="text" value="" name="email">
          </span>
    </div>

    <div class="jb-popup-option">
       <span class="jb-popup-label"></span>
       <span class="jb-popup-value">
       <input type="button" class="standard-button" value="Cancel" name="submit:Cancel|1">
       <input type="submit" class="standard-button" value="Send" name="submit:Send|1">
      </span>
    </div>
</div>

 </div>
<!-- "fulltext-controlbox-section" -->



 <div class="fulltext-right-outline">
    <div id="fulltext-right-outline-title"><h2>Outline</h2></div>
   <div id="fulltext-right-outline-links">
     <ul>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#12">Summary:<wbr></a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#16">METHODS AND MATERIALS</a>
    
      <ul>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#18">Chemicals</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#20">Cell preparation</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#24">Intracellular cAMP measurement</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#28">Platelet aggregation</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#30">Isolated heart studies</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#35">Statistical analysis</a>
    
   </li>

</ul>

    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#37">RESULTS</a>
    
      <ul>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=434f4e1a73d37e8c78e6973bbb18ee808a460901619e4049f7a754407aa31591c119ae00af6cb03ff5d63f97b2e72461c7703d28d25b18cdd87ba63be34dfe1fed00016bc1ae9736c04de7e9cecd3910dd7ab4d50a4fec580038bb21cd8ced2d8322a31095a10a29e8d211250b42810b313a3c3c79d2e05fe6ca31896eab57906c5650cec0cd87e2056c9b8ee7e061de3ff26f18a4869bdc7ffec9dcbd27df74432f4569fd380edf64a15c8a4facee78adaee9d8f57513c5ebec7a0b71a39865bb5a4ad7caaab327f1a7f577c1b6006648d5bece00a5ef6f8009bd1ace504fa1fee8a1281910076f19013375652cd616bf99ef00f7c6525a6a758bf10012838d2675224149922b39#38">cAMP studies</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#42">Platelet aggregation</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#44">Isolated heart studies</a>
    
   </li>

</ul>

    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#48">DISCUSSION</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#56">REFERENCES</a>
    
   </li>

   <li>
    <a class="tlink fulltext-outline-links" href="http://ovidsp.tx.ovid.com/sp-3.25.0a/ovidweb.cgi?QS2=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#image-gallery">IMAGE GALLERY</a>
    
   </li>

</ul>

   </div>
</div>



</div> <!-- "fulltext-controlbox" -->
  </td>
 </tr>
</tbody></table>

</form>

</div> <!-- main-content -->

<div id="ovid-footer"><div id="footer-buttons-lower" style="width: auto; float: right;"><a class="tlink" href="http://www.ovid.com/site/about/index.jsp?top=42" target="_blank">About Us</a><a class="tlink" href="http://www.ovid.com/site/support/techSupportForm.jsp?top=34&amp;mid=35" target="_blank">Contact Us</a><a class="tlink" href="http://www.ovid.com/site/about/terms.jsp" target="_blank">Terms of Use</a></div><div id="footer-copyright-build"><div id="footer-copyright" style="width: auto;">© 2017 <a class="copyright-link" href="http://www.ovid.com/" target="_blank">Ovid Technologies, Inc.</a> All rights reserved.</div><div id="footer-build"> OvidSP_UI03.25.00.058, SourceID 108203</div></div></div></div> <!-- below-banner -->



</body></html>